All Flightpath Biosciences, Inc. articles
-
NewsFlightpath Biosciences licenses microbiome-sparing antibiotic developed at Illinois
Flightpath Biosciences, Inc., has licensed a class of antibiotics developed at the University of Illinois Urbana-Champaign. The original antibiotic agent, lolamicin, effectively treated bacterial infections in animal models of disease without wiping out beneficial gut microbes.